Directors & Officers
| Name | Title | Year Born |
|---|---|---|
| Dr. Andre P. Boulet Ph.D. | Chair of the Board & CEO | 1959 |
| Mr. Dennis Turpin CA, CPA | CFO & Director | 1963 |
| Mr. Luc D. Gregoire CA, CPA | Executive Vice-President of Strategy | 1960 |
DVHG
Devonian Health Group Inc.
Employees
8
Phone
581-632-0692
Fiscal year end
July
Address
360, rue des Entrepreneurs, Québec, QC, Canada, G5V 4T1
5.88
+0.00 (+0.00%)
USD · OTCQB
52-week range
4.27
10.65
Trading at 25% of the 52-week range
Market Cap
16.34M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
1.79
Div. Yield
N/A
% Institutions
0.292%
% Insiders
12.04%
1 Year
+37.7%3 Year
-54.2%10 Year
-76.0%Description
Devonian Health Group Inc. operates as a clinical stage biopharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs in Canada and Internationally. It engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops pantoprazole magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the purgenesis name. Devonian Health Group Inc. was founded in 2017 and is headquartered in Québec, Canada.
Actions
Add an action for DVHGF.US, or sign in to see your action list.
People
Financial Highlights
Market Cap:
$16.34M
EBITDA:
$-5.92M
Book Value:
$1.79
Earnings/Share:
$-1.54
Profit Margin:
-204.08%
Operating Margin:
-1,096.23%
ROA (TTM):
-24.50%
ROE (TTM):
-77.33%
Revenue (TTM):
$3.00M
Revenue/Share (TTM):
$1.11
Earnings Growth (YOY):
0.00%
Revenue Growth (YOY):
-97.60%
Valuation Metrics
Enterprise Value:
$15.92M
Trailing P/E:
0.00
Forward P/E:
0.00
Shares Statistics
Shares Outstanding:
2.78M
Shares Float:
1.94M
% Insiders:
12.04%
% Institutions:
0.292%
Stock Price History
1 Year Price History
3 Years Price History
10 Years Price History
Max Price History
Financial Charts
Revenue, Net Income & Operating Cash Flow (Yearly)
Change % vs Prior Year
Revenue, Net Income & Operating Cash Flow (Quarterly)
Change % vs Prior Quarter
Operating Expenses (Yearly)
Operating Expenses (Quarterly)
Balance Sheet (Yearly)
Balance Sheet (Quarterly)
Assets Breakdown (Yearly)
Assets Breakdown (Quarterly)
Liabilities Breakdown (Yearly)
Liabilities Breakdown (Quarterly)
Income Statement Waterfall
Line Item
Step Type
Value
Revenue
adjust
$23.59M
Cost of Goods Sold
adjust
$-15.03M
Gross Profit
subtotal
$8.56M
SG&A
adjust
$-7.32M
R&D
adjust
$-2.01M
Other Operating Expense
adjust
$-15.03M
Operating Income
subtotal
$-770.98K
Other / Non-Operating Items
adjust
$-5.24M
Net Income
subtotal
$-6.01M
Earnings Per Share (EPS) History
Financial Ratios
📦 Raw API Data (JSON Explorer)
Comprehensive raw data returned from the EOD Fundamentals API. Expand sections below to drill down.